000132862 001__ 132862
000132862 005__ 20240229105036.0
000132862 0247_ $$2doi$$a10.1371/journal.pone.0194989
000132862 0247_ $$2pmid$$apmid:29596469
000132862 0247_ $$2pmc$$apmc:PMC5875788
000132862 0247_ $$2altmetric$$aaltmetric:35118297
000132862 037__ $$aDKFZ-2018-00505
000132862 041__ $$aeng
000132862 082__ $$a500
000132862 1001_ $$00000-0002-9607-3866$$aThierauf, Julia$$b0
000132862 245__ $$aLow SOX2 expression marks a distinct subset of adenoid cystic carcinoma of the head and neck and is associated with an advanced tumor stage.
000132862 260__ $$aLawrence, Kan.$$bPLoS$$c2018
000132862 3367_ $$2DRIVER$$aarticle
000132862 3367_ $$2DataCite$$aOutput Types/Journal article
000132862 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1526386404_1623
000132862 3367_ $$2BibTeX$$aARTICLE
000132862 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132862 3367_ $$00$$2EndNote$$aJournal Article
000132862 520__ $$aThe transcription factor SOX2 has been identified as a lineage survival oncogene in squamous cell carcinoma and copy number gain is a common event in several human malignancies including head and neck cancer. However, the regulation and function of SOX2 during carcinogenesis as well as its prognostic value appears to be highly context dependent. As an example, high SOX2 expression in lung squamous cell carcinoma (SCC) is related to a favorable prognosis, while it is associated with poor outcome in lung adenocarcinoma. More recently, higher SOX2 levels and improved survival was also reported for head and neck SCC (HNSCC), and silencing of SOX2 expression in HNSCC cell lines revealed a mesenchymal-like phenotype with prominent vimentin expression. So far, SOX2 expression and its clinical relevance for other head and neck cancers, such as adenoid cystic carcinoma (HNACC) have not been sufficiently investigated.SOX2, vimentin and E-cadherin expression was assessed by immunohistochemical staining on serial sections from formalin fixed and paraffin embedded tissue samples of a patient cohort (n = 45) with primary ACC and correlated with patient and tumor characteristics as well as survival.High SOX2 expression was found in 14 (31%) primary tumor specimens and was significantly correlated with a N0 lymph node status (p = 0.04), while low SOX2 expression was correlated with a solid growth pattern (p = 0.031). Of the 45 patients, 27 tumor samples resembled an EMT-like phenotype, as assessed by high vimentin and low E-cadherin levels. However, in HNACC SOX2 levels were neither correlated with vimentin nor with E-cadherin expression, further supporting a context dependent regulation and function of SOX2 in distinct tumor entities.The absence of SOX2 was predominantly found in solid HNACC, which are characterized by a more aggressive phenotype in ACC. However, the underlying molecular mechanisms of SOX2 regulation and function in distinct HNACC subgroups remain to be fully elucidated.
000132862 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132862 588__ $$aDataset connected to CrossRef, PubMed,
000132862 7001_ $$aWeissinger, Stephanie E$$b1
000132862 7001_ $$aVeit, Johannes A$$b2
000132862 7001_ $$aAffolter, Annette$$b3
000132862 7001_ $$0P:(DE-HGF)0$$aLaureano, Natalia K$$b4
000132862 7001_ $$aBeutner, Dirk$$b5
000132862 7001_ $$aHeiduschka, Gregor$$b6
000132862 7001_ $$aKadletz, Lorenz$$b7
000132862 7001_ $$aMeyer, Moritz$$b8
000132862 7001_ $$aQuaas, Alexander$$b9
000132862 7001_ $$aPlinkert, Peter$$b10
000132862 7001_ $$aHoffmann, Thomas K$$b11
000132862 7001_ $$0P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aHess, Jochen$$b12$$eLast author$$udkfz
000132862 773__ $$0PERI:(DE-600)2267670-3$$a10.1371/journal.pone.0194989$$gVol. 13, no. 3, p. e0194989 -$$n3$$pe0194989 -$$tPLoS one$$v13$$x1932-6203$$y2018
000132862 909CO $$ooai:inrepo02.dkfz.de:132862$$pVDB
000132862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000132862 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132862 9141_ $$y2018
000132862 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPLOS ONE : 2015
000132862 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132862 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132862 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132862 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000132862 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000132862 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000132862 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000132862 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000132862 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132862 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132862 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132862 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record
000132862 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132862 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132862 9201_ $$0I:(DE-He78)G405-20160331$$kG405$$lMolekulare Grundlagen von HNO-Tumoren$$x0
000132862 980__ $$ajournal
000132862 980__ $$aVDB
000132862 980__ $$aI:(DE-He78)G405-20160331
000132862 980__ $$aUNRESTRICTED